FDA OKs Phase 1 study of two-component immunotherapy
The FDA approved the launch of a clinical trial to evaluate the safety and effectiveness of its two-component immunotherapy for lupus.| Lupus News Today
The FDA approved the launch of a clinical trial to evaluate the safety and effectiveness of its two-component immunotherapy for lupus.| Lupus News Today
One year of treatment with dapirolizumab pegol reduced fatigue and disease activity in people with SLE in a Phase 3 trial.| Lupus News Today
A CAR T-cell therapy cleared disease-causing autoantibodies from the bloodstream of eight SLE patients without compromising vaccine response.| Lupus News Today
Author archive page for Lindsey Shapiro.| Lupus News Today
Scientist Akiko Iwasaki will receive award to investigate whether ancient viral DNA in our cells is a potential trigger for lupus.| Lupus News Today
